Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Capital Expenditures for 3 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 259.69% to -$1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $292000.0, a 412.28% increase, with the full-year FY2025 number at $292000.0, up 412.28% from a year prior.
  • Capital Expenditures was -$1.9 million for Q4 2025 at Artiva Biotherapeutics, down from $600000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q2 2025 to a low of -$1.9 million in Q4 2025.
  • A 3-year average of $30100.0 and a median of $282500.0 in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 3830.77% in 2025; the steepest drop was 259.69% in 2025.
  • Artiva Biotherapeutics' Capital Expenditures stood at -$599000.0 in 2023, then rose by 13.02% to -$521000.0 in 2024, then tumbled by 259.69% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Capital Expenditures are -$1.9 million (Q4 2025), $600000.0 (Q3 2025), and $1.1 million (Q2 2025).